Results 141 to 150 of about 955 (158)

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Lancet, The, 2011
Fritz Offner, David Belada, Pierre Feugier   +2 more
exaly  

Prevention of incisional hernia with prophylactic onlay and sublay mesh reinforcement versus primary suture only in midline laparotomies (PRIMA): 2-year follow-up of a multicentre, double-blind, randomised controlled trial

Lancet, The, 2017
David van Klaveren, Panagiotis Fikatas, René Fortelny   +2 more
exaly  

PRIMA, non nocere: a reply from the authors

Lancet, The, 2018
Johannes Jeekel
exaly  

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

Cancers, 2017
Ahmad Najem, Sven Saussez, Ahmad Awada
exaly  

Tu1970 Restoring Wild-Type p53 Activity Using Apr-246/ Prima-1Met Significantly Suppresses Tumour Growth and Overcomes Chemotherapeutic Resistance in Esophageal Adenocarcinoma

Gastroenterology, 2015
David Liu, Nicholas J. Clemons, Matthew Read, Carleen Cullinane, Cuong Duong, Wayne A. Phillips   +5 more
openaire   +1 more source

Effect of quercetin and prima-1MET (P53 activator) combination therapy on P53 mutant type human colon cancer cells (COLO-320)

International Journal of pharma and Bio Sciences, 2019
CHANDRA SEKHAR PASULA, DR. SAVITHIRI SHIVAKUMAR, YASODHA LAKSHMI T, RAJA RATNA REDDY Y, DR. S. RAMA MOORTHY   +4 more
openaire   +1 more source

PRIMA-1MET/APR-246 Can Partially Rescue In Vitro Cell Adhesion of Patient-Derived Junctional Epidermolysis Bullosa Epidermal Cells

Journal of Investigative Dermatology
Clément Berthy, Laurent Gagnoux-Palacios, Marine Madrange, Christine Bodemer, Nicolas Cagnard, Smail Hadj-Rabia, Isabelle Petit, Daniel Aberdam   +7 more
openaire   +2 more sources

PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2

Oncogene, 2008
Boris Zhivotovsky
exaly  

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines

Investigational New Drugs, 2014
Ana Lucia L Abujamra, Caroline Brunetto de Farias, Barbara Alemar   +2 more
exaly  

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Journal of Clinical Oncology, 2019
Emmanuel Bachy, John F Seymour, Fritz Offner   +2 more
exaly